Cellipont Bioservices announced a strategic collaboration with Ronawk to accelerate the scalable expansion of high-quality mesenchymal stem cells (MSCs). The partnership addresses key industry challenges in scalability, consistency, capital efficiency, and therapeutic readiness for advanced biologics and regenerative medicine applications.
By combining Cellipont's deep expertise in cGMP manufacturing and process development with Ronawk's pioneering Bio-OS™ platform, which recreates the natural cellular microenvironment, the companies aim to enhance the quality, reproducibility, and efficiency of MSC production - paving the way for the next generation of cell-based therapies.
"Cellipont is committed to enabling the next generation of cell therapies," said Darren Head, CEO of Cellipont Bioservices. "Integrating Ronawk's Bio-OS™ platform into our manufacturing capabilities allows us to overcome bottlenecks in MSC expansion and deliver scalable, consistent, and cost-effective therapeutic products to our partners and, ultimately, to patients."
"Expanding MSCs at scale while preserving quality, viability, and potency has long been a challenge in regenerative medicine," said A.J. Mellott, Ph.D., CEO of Ronawk. "By partnering with Cellipont, we're combining advanced process know-how with innovative platform technology to deliver higher-quality cells for use across biologics, exosome therapeutics, and regenerative medicine."
MSCs are among the most widely studied and clinically promising stem cell types, valued for their regenerative and immunomodulatory properties. Yet large-scale, consistent, and cost-effective manufacturing remains a limiting factor for broad clinical adoption. This collaboration between Cellipont and Ronawk seeks to close that gap - offering new pathways to scalable, high-quality MSC production that can accelerate therapeutic development across the biotech landscape.